AACR Annual Meeting 2018: Off-the-shelf CAR T-cell Immunotherapy – Are we There Yet?

A study presented at the AACR Annual Meeting 2018 discussed preliminary data on an off-the-shelf, T-cell receptor (TCR)-less, dual-targeted CD19-CAR T-cell product, FT819. In proof-of-concept preclinical studies, FT819 was found …

Read More

Improving the Effectiveness of CAR T-cell Immunotherapy

A study presented in the AACR Annual Meeting 2018 Media Preview webinar, held March 15, examined closely a key ingredient necessary to make effective chimeric antigen receptor (CAR) T cells – the T cells of a patient. The researchers behind this study have identified one potential reason for why we have not been successful in making CAR T-cell therapy work against solid tumors, and offer a solution.

Read More